Sanctuary Advisors LLC Purchases 13,569 Shares of Gilead Sciences, Inc. $GILD

Sanctuary Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 221,511 shares of the biopharmaceutical company’s stock after purchasing an additional 13,569 shares during the period. Sanctuary Advisors LLC’s holdings in Gilead Sciences were worth $27,188,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GILD. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Financial Consulate Inc. lifted its holdings in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. MTM Investment Management LLC lifted its holdings in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Millstone Evans Group LLC lifted its holdings in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

GILD opened at $130.40 on Monday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The firm has a market capitalization of $161.86 billion, a PE ratio of 19.26, a PEG ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The business’s 50-day simple moving average is $142.44 and its 200 day simple moving average is $132.22.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research reports. Leerink Partners boosted their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Daiwa Securities Group boosted their price target on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Citigroup boosted their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $157.35.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider owned 128,779 shares in the company, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 178,640 shares of company stock worth $26,691,550. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.